Inicio | Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations
Publicado clinical_trials Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations has 2 revisions.
RevisiónEstado
Guardado 19/07/2023 - 2:26pm por Gladys
Revisión actual (publicada)
Guardado 22/05/2021 - 5:24pm por Gladys
archivadas
Equipo de Trabajo del RPCEC | CENCEC - MINSAP
rpcec@cencec.sld.cu
Calle 5ta A Edificio CECMED-CENCEC 2do piso e/ 60 y 62 Miramar, Playa.CP 11300. La Habana, Cuba
Telef: (537) 216-4126 | (537) 216-4212 | (537) 216-4218.
Copyright © 2014-2022 All Rights Reserved.